QuidelOrtho Corporation (QDEL)Healthcare | Medical Devices | San Diego, United States | NasdaqGS
14.74 USD
-0.58
(-3.786%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 14.70 -0.04 (-0.040%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:55 a.m. EDT
The investment case here is severely compromised by a deteriorating business trajectory. Despite trading at a fraction of book value, the company has suffered five consecutive years of negative annual returns, with the most recent year seeing a sharp decline. This multi-year structural decline overrides any apparent cheapness in valuation metrics; the market is correctly pricing in a failing growth story and operational struggles, as indicated by negative operating margins and a lack of free cash flow generation. The absence of any dividend policy leaves shareholders exposed to pure equity risk without income cushion. On the short end, while the stock has recently stabilized near its lows, the heavy concentration of speculative put options suggests traders are still bracing for further drops, making a high-conviction entry premature. The statistical forecast offers no directional clarity, reinforcing the need to rely on the stark fundamental reality: a company in a prolonged secular decline. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.143209 |
| AutoETS | 0.149672 |
| AutoARIMA | 0.149673 |
| AutoTheta | 0.169641 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 0.44 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.095 |
| Excess Kurtosis | -0.93 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 173.277 |
| Revenue per Share | 39.269 |
| Market Cap | 1,010,801,728 |
| Forward P/E | 10.22 |
| Beta | 0.69 |
| Profit Margins | -39.20% |
| Previous Name | Quidel Corporation |
| Website | https://www.quidelortho.com |
As of Aug. 22, 2026, 3:55 a.m. EDT: Speculators are aggressively positioning for downside protection, evidenced by massive open interest in deep out-of-the-money puts (strikes $7.50 and $10.00) relative to calls. While there is some volume in far-out calls ($25-$30 strikes), the overwhelming capital deployment is in put writing and buying, suggesting a consensus view of continued volatility and potential further declines rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.45769912 |
| Address1 | 9,975 Summers Ridge Road |
| All Time High | 306.72 |
| All Time Low | 1.6875 |
| Ask | 18.81 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 2.7 - Hold |
| Average Daily Volume10 Day | 1,381,950 |
| Average Daily Volume3 Month | 1,595,264 |
| Average Volume | 1,595,264 |
| Average Volume10Days | 1,381,950 |
| Beta | 0.693 |
| Bid | 14.71 |
| Bid Size | 1 |
| Board Risk | 2 |
| Book Value | 25.987 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 14.74 |
| Current Ratio | 1.386 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 15.09 |
| Day Low | 14.62 |
| Debt To Equity | 173.277 |
| Display Name | QuidelOrtho |
| Earnings Call Timestamp End | 1,786,050,000 |
| Earnings Call Timestamp Start | 1,786,050,000 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | 484,600,000 |
| Ebitda Margins | 0.18121 |
| Enterprise To Ebitda | 8.178 |
| Enterprise To Revenue | 1.482 |
| Enterprise Value | 3,962,901,760 |
| Eps Current Year | 0.77449 |
| Eps Forward | 1.44209 |
| Eps Trailing Twelve Months | -14.85 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 858 453 4338 |
| Fifty Day Average | 15.8072 |
| Fifty Day Average Change | -1.0672007 |
| Fifty Day Average Change Percent | -0.06751358 |
| Fifty Two Week Change Percent | -45.769913 |
| Fifty Two Week High | 35.58 |
| Fifty Two Week High Change | -20.840002 |
| Fifty Two Week High Change Percent | -0.5857223 |
| Fifty Two Week Low | 9.92 |
| Fifty Two Week Low Change | 4.8199997 |
| Fifty Two Week Low Change Percent | 0.48588705 |
| Fifty Two Week Range | 9.92 - 35.58 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 665,418,600,000 |
| Float Shares | 61,168,595 |
| Forward Eps | 1.44209 |
| Forward P E | 10.221275 |
| Free Cashflow | 146,762,496 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 6,500 |
| Fullday Change | -0.58 |
| Fullday Change Percent | -3.7859 |
| Fullday Price | 14.7 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.44858003 |
| Gross Profits | 1,199,600,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00894 |
| Held Percent Institutions | 1.24865 |
| Implied Shares Outstanding | 68,575,427 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,766,880,000 |
| Long Business Summary | QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California. |
| Long Name | QuidelOrtho Corporation |
| Market | us_market |
| Market Cap | 1,010,801,728 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_127881 |
| Most Recent Quarter | 1,782,604,800 |
| Name Change Date | 2,026-08-29 |
| Net Income To Common | -1,048,400,000 |
| Next Fiscal Year End | 1,798,416,000 |
| Non Diluted Market Cap | 1,049,889,787 |
| Number Of Analyst Opinions | 3 |
| Open | 15.09 |
| Operating Cashflow | -57,200,000 |
| Operating Margins | -0.020920001 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Peg Ratio | 2.06 |
| Phone | 858 552 1100 |
| Post Market Change | -0.03999996 |
| Post Market Change Percent | -0.27137017 |
| Post Market Price | 14.7 |
| Post Market Time | 1,787,959,806 |
| Prev Name | Quidel Corporation |
| Previous Close | 15.32 |
| Price Eps Current Year | 19.03188 |
| Price Hint | 2 |
| Price To Book | 0.5672067 |
| Price To Sales Trailing12 Months | 0.37798283 |
| Profit Margins | -0.39203998 |
| Quick Ratio | 0.596 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.66667 |
| Region | US |
| Regular Market Change | -0.58 |
| Regular Market Change Percent | -3.7859 |
| Regular Market Day High | 15.09 |
| Regular Market Day Low | 14.62 |
| Regular Market Day Range | 14.62 - 15.09 |
| Regular Market Open | 15.09 |
| Regular Market Previous Close | 15.32 |
| Regular Market Price | 14.74 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 1,207,588 |
| Return On Assets | 0.0038299998 |
| Return On Equity | -0.45905998 |
| Revenue Growth | 0.028 |
| Revenue Per Share | 39.269 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 68,575,427 |
| Shares Percent Shares Out | 0.2182 |
| Shares Short | 14,962,267 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 11,802,749 |
| Short Name | QuidelOrtho Corporation |
| Short Percent Of Float | 0.2975 |
| Short Ratio | 10.38 |
| Source Interval | 15 |
| State | CA |
| Symbol | QDEL |
| Target High Price | 20.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 14.66667 |
| Target Median Price | 12.0 |
| Total Cash | 123,400,000 |
| Total Cash Per Share | 1.799 |
| Total Debt | 3,075,500,032 |
| Total Revenue | 2,674,200,064 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -14.85 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 19.6694 |
| Two Hundred Day Average Change | -4.9293995 |
| Two Hundred Day Average Change Percent | -0.25061262 |
| Type Disp | Equity |
| Volume | 1,207,588 |
| Website | https://www.quidelortho.com |
| Zip | 92,121 |